Pyrazolopyrimidines as Cyclin Dependent Kinase Inhibitors

P 2004

Pyrazolopyrimidines as Cyclin Dependent Kinase Inhibitors

GUZI, Timothy, Kamil PARUCH, Michael DWYER, Ronald DOLL, Viyyoor GIRIJAVALLABHAN et. al.

Basic information

Original name

Pyrazolopyrimidines as Cyclin Dependent Kinase Inhibitors

Name in Czech

Pyrazolopyrimidines as Cyclin Dependent Kinase Inhibitors

Authors

GUZI, Timothy (840 United States of America), Kamil PARUCH (203 Czech Republic, guarantor), Michael DWYER (840 United States of America), Ronald DOLL (840 United States of America), Viyyoor GIRIJAVALLABHAN (840 United States of America), Alan MALLAMS (840 United States of America), Carmen ALVAREZ (840 United States of America), Kartik KEERTIKAR (840 United States of America), Jocelyn RIVERA (840 United States of America), Tin-Yau CHAN (840 United States of America), Vincent MADISON (840 United States of America), Thierry FISCHMANN (840 United States of America), Lawrence DILLARD (840 United States of America), Vinh TRAN (840 United States of America), Zhen HE (840 United States of America), Ray JAMES (840 United States of America), Haengsoon PARK (840 United States of America), Vidyadhar PARADKAR (840 United States of America) and Douglas HOBBS (840 United States of America)

Edition

Number: WO 2004/022561 A1, Publisher: World Intellectual Property Organization, Place of publication: USA, Owner's name: Schering-Plough; Pharmacopeia, 2004

Other information

Language

English

Type of outcome

Patent

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

RIV identification code

RIV/00216224:14310/04:00036002

Organization unit

Faculty of Science

Keywords (in Czech)

cyclin dependent kinase; inhibitor; cancer

Keywords in English

cyclin dependent kinase; inhibitor; cancer

Abstract

ORIG CZ

V originále

The title pyrazolo[1,5-a]pyrimidines [I R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases assocd. with the CDKs such as cancer, were prepd. Thus, reacting II (prepn. given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 .mu.M and 0.029 .mu.M against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical compn. comprising the compd. I is claimed.

In Czech

viz Anotace

Citovat

GUZI, Timothy, Kamil PARUCH, Michael DWYER, Ronald DOLL, Viyyoor GIRIJAVALLABHAN, Alan MALLAMS, Carmen ALVAREZ, Kartik KEERTIKAR, Jocelyn RIVERA, Tin-Yau CHAN, Vincent MADISON, Thierry FISCHMANN, Lawrence DILLARD, Vinh TRAN, Zhen HE, Ray JAMES, Haengsoon PARK, Vidyadhar PARADKAR and Douglas HOBBS. Pyrazolopyrimidines as Cyclin Dependent Kinase Inhibitors. 2004.

@misc{838412,
   author = {Guzi, Timothy and Paruch, Kamil and Dwyer, Michael and Doll, Ronald and Girijavallabhan, Viyyoor and Mallams, Alan and Alvarez, Carmen and Keertikar, Kartik and Rivera, Jocelyn and Chan, TinandYau and Madison, Vincent and Fischmann, Thierry and Dillard, Lawrence and Tran, Vinh and He, Zhen and James, Ray and Park, Haengsoon and Paradkar, Vidyadhar and Hobbs, Douglas},
   keywords = {cyclin dependent kinase; inhibitor; cancer},
   language = {eng},
   title = {Pyrazolopyrimidines as Cyclin Dependent Kinase Inhibitors},
   year = {2004}
}

TY  - PAT
ID  - 838412
AU  - Guzi, Timothy - Paruch, Kamil - Dwyer, Michael - Doll, Ronald - Girijavallabhan, Viyyoor - Mallams, Alan - Alvarez, Carmen - Keertikar, Kartik - Rivera, Jocelyn - Chan, Tin-Yau - Madison, Vincent - Fischmann, Thierry - Dillard, Lawrence - Tran, Vinh - He, Zhen - James, Ray - Park, Haengsoon - Paradkar, Vidyadhar - Hobbs, Douglas
PY  - 2004
TI  - Pyrazolopyrimidines as Cyclin Dependent Kinase Inhibitors
KW  - cyclin dependent kinase
KW  - inhibitor
KW  - cancer
N2  - The title pyrazolo[1,5-a]pyrimidines [I R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases assocd. with the CDKs such as cancer, were prepd. Thus, reacting II (prepn. given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 .mu.M and 0.029 .mu.M against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical compn. comprising the compd. I is claimed.
ER  -

GUZI, Timothy, Kamil PARUCH, Michael DWYER, Ronald DOLL, Viyyoor GIRIJAVALLABHAN, Alan MALLAMS, Carmen ALVAREZ, Kartik KEERTIKAR, Jocelyn RIVERA, Tin-Yau CHAN, Vincent MADISON, Thierry FISCHMANN, Lawrence DILLARD, Vinh TRAN, Zhen HE, Ray JAMES, Haengsoon PARK, Vidyadhar PARADKAR and Douglas HOBBS. \textit{Pyrazolopyrimidines as Cyclin Dependent Kinase Inhibitors}. 2004.

Detailed Information on Publication Record